宫颈托预防短宫颈者早产:TOPS随机临床试验
这项多中心随机非盲试验纳入544例孕16周0天至23周6天、经阴道超声宫颈长度≤20 mm的单胎非临产者,比较宫颈托与常规护理。结果显示37周前分娩或胎死率宫颈托组45.5%对常规护理组45.6%(RR 1.00,95%CI 0.83-1.20),胎/新生儿/婴儿死亡率宫颈托组13.3%对常规护理组6.8%(RR 1.94,95%CI 1.13-3.32)。
要点
- 宫颈托未降低37周前分娩或胎死风险(45.5%对45.6%,RR 1.00)。
- 宫颈托组胎/新生儿/婴儿死亡率13.3%,高于常规护理组6.8%(RR 1.94)。
- 研究因胎儿或新生儿/婴儿死亡担忧及无效性提前终止招募。
核心结论
- 宫颈托未降低单胎短宫颈非临产者37周前分娩风险,且与更高的胎/新生儿/婴儿死亡率相关。
研究设计与样本
- 多中心、随机、非盲试验,2017年2月至2021年11月5日在美国12个中心开展。
- 纳入544例(计划样本量850例的64%)单胎妊娠、孕16周0天至23周6天、经阴道超声宫颈长度≤20 mm的非临产者,排除既往自发性早产史者。
- 按1:1随机接受培训临床医生放置宫颈托(n=280)或常规护理(n=264),阴道孕酮使用由治疗临床医生决定。
主要发现
- 主要结局(37周前分娩或胎死)在宫颈托组127例(45.5%)发生,常规护理组127例(45.6%)发生(相对风险1.00,95%CI 0.83-1.20)。
- 胎/新生儿/婴儿死亡在宫颈托组发生率为13.3%,常规护理组为6.8%(相对风险1.94,95%CI 1.13-3.32)。
- 98.9%的参与者接受了阴道孕酮。
- 第三次中期分析后,因对胎儿或新生儿/婴儿死亡的担忧及无效性,研究停止招募。
关键数值与推荐
- 主要结局为37周前分娩或胎死。
- 宫颈托组主要结局45.5%,常规护理组45.6%,相对风险1.00(95%CI 0.83-1.20)。
- 胎/新生儿/婴儿死亡率宫颈托组13.3%,常规护理组6.8%,相对风险1.94(95%CI 1.13-3.32)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因对胎儿或新生儿/婴儿死亡的担忧及无效性提前终止招募,仅入组544例(计划样本量850例的64%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A short cervix as assessed by transvaginal ultrasound is an established risk factor for preterm birth. Study findings for a cervical pessary to prevent preterm delivery in singleton pregnancies with transvaginal ultrasound evidence of a short cervix have been conflicting. OBJECTIVE: To determine if cervical pessary placement decreases the risk of preterm birth or fetal death prior to 37 weeks among individuals with a short cervix. DESIGN, SETTING, AND PARTICIPANTS: We performed a multicenter, randomized, unmasked trial comparing a cervical pessary vs usual care from February 2017 through November 5, 2021, at 12 centers in the US. Study participants were nonlaboring individuals with a singleton pregnancy and a transvaginal ultrasound cervical length of 20 mm or less at gestations of 16 weeks 0 days through 23 weeks 6 days. Individuals with a prior spontaneous preterm birth were excluded. INTERVENTIONS: Participants were randomized 1:1 to receive either a cervical pessary placed by a trained clinician (n = 280) or usual care (n = 264). Use of vaginal progesterone was at the discretion of treating clinicians. MAIN OUTCOME AND MEASURES: The primary outcome was delivery or fetal death prior to 37 weeks. RESULTS: A total of 544 participants (64%) of a planned sample size of 850 were enrolled in the study (mean age, 29.5 years [SD, 6 years]). Following the third interim analysis, study recruitment was stopped due to concern for fetal or neonatal/infant death as well as for futility. Baseline characteristics were balanced between participants randomized to pessary and those randomized to usual care; 98.9% received vaginal progesterone. In an as-randomized analysis, the primary outcome occurred in 127 participants (45.5%) randomized to pessary and 127 (45.6%) randomized to usual care (relative risk, 1.00; 95% CI, 0.83-1.20). Fetal or neonatal/infant death occurred in 13.3% of those randomized to receive a pessary and in 6.8% of those randomized to receive usual care (relative risk, 1.94; 95% CI, 1.13-3.32). CONCLUSIONS AND RELEVANCE: Cervical pessary in nonlaboring individuals with a singleton gestation and with a cervical length of 20 mm or less did not decrease the risk of preterm birth and was associated with a higher rate of fetal or neonatal/infant mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02901626.
引用
- Hoffman MK, Clifton RG, Biggio JR, et al. Cervical Pessary for Prevention of Preterm Birth in Individuals With a Short Cervix: The TOPS Randomized Clinical Trial. JAMA. 2023. PMID: 37490086. doi:10.1001/jama.2023.10812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。